AC Immune to Present Progress of Alzheimer’s Disease Programs targeting Abeta and Tau at the 15th CTAD Conference
November 23, 2022 07:30 ET
|
AC Immune SA
Next generation SupraAntigen® liposomal vaccine platform augments immunization against pathological targets of Alzheimer’s diseaseNew data on anti-phospho-Tau vaccines confirm safety, tolerability and...
Rewind Therapeutics Appoints Irene Knuesel, PhD, as Chief Scientific Officer
October 19, 2022 04:00 ET
|
AKAMPION
- Former Roche Head of Neuroimmunology strengthens Rewind´s neuroimmunology and neurodegeneration expertise Leuven, Belgium, October 19, 2022 --- Rewind Therapeutics, a company developing...
1ST Biotherapeutics, Inc., Announces Positive Phase I Data of c-Abl Inhibitor in Neurodegeneration
October 18, 2022 03:00 ET
|
AKAMPION
- Compound demonstrates excellent safety and tolerability in single ascending dose trial - Efficient penetration of blood-brain barrier YONGIN, South Korea, October 18, 2022 -- 1ST...
BioJiva Reports Results of Pilot Phase 2 Clinical Trial of RT001 in Patients with Amyotrophic Lateral Sclerosis (ALS)
September 15, 2022 07:00 ET
|
BioJiva, LLC
Signals of Clinical Benefit Detected in Small Phase 2 Study, Suggesting Potential to Show Statistically Significant Therapeutic Benefit in Larger, Targeted TrialConsistent Benefit vs. Placebo in...
Vaccinex, Inc. Announces Presentation at the 2022 Alzheimer’s Association International Conference Updating the SIGNAL-AD Study of Pepinemab in Patients with Alzheimer’s Disease
July 29, 2022 07:00 ET
|
Vaccinex, Inc.
ROCHESTER, N.Y., July 29, 2022 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative...
Elixiron Immunotherapeutics Receives Grant From the Alzheimer's Association to Trial Microglia-Targeting Immunotherapy
July 12, 2022 11:01 ET
|
Elixiron Immunotherapeutics
SAN FRANCISCO, July 12, 2022 (GLOBE NEWSWIRE) -- Elixiron Immunotherapeutics, a clinical stage drug development company announced today that it has received a new grant from the Alzheimer's...
reMYND’s novel Alzheimer program reports excellent brain exposure and safety profile in Phase 1; transitioning into Phase 2a
May 03, 2022 02:00 ET
|
reMYND
PRESS RELEASE reMYND’s novel Alzheimer program reports excellent brain exposure and safety profile in Phase 1; transitioning into Phase 2a Leuven Belgium, 03 May 2022: reMYND NV, a clinical stage...
Neurocentria Obtains FDA Approval to Conduct Pivotal Phase IIb/III Clinical Trial for Testing Safety and Efficacy of Drug Candidate NRCT-101SR in Adults With ADHD
February 15, 2022 09:00 ET
|
Neurocentria, Inc
WALNUT CREEK, N.C., Feb. 15, 2022 (GLOBE NEWSWIRE) -- Neurocentria Inc., a privately held late-stage biotechnology company developing novel therapies for Alzheimer's disease, Attention Deficit...
Enterin Announces Publication of Exciting Discoveries About the Enterin Nervous System
November 19, 2021 09:00 ET
|
Enterin Inc.
PHILADELPHIA, Nov. 19, 2021 (GLOBE NEWSWIRE) -- Enterin Inc., a privately held Philadelphia-based clinical-stage biopharmaceutical company pioneering novel treatments for neurodegenerative and...
Positive Results from Studies of Retrotope’s RT011 in Animal Models of Retinal Degeneration to be Featured in Oral Presentations at 2nd Annual Dry AMD Therapeutic Development Summit
October 19, 2021 07:00 ET
|
Retrotope
Data Demonstrate RT011 Offers Dose-Dependent Protection Against Retinal Lipid Peroxidation (LPO) and Cell Damage, as well as Preservation of Visual Function Findings Provide Rationale for Advancement...